nach oben

Erschienen in:

05.08.2020 | Urology - Original Paper

Prognostic value of immunological profile based on CD8+ and FoxP3+ T lymphocytes in the peritumoral and intratumoral subsites for renal cell carcinoma

verfasst von: Kerem Teke, Busra Yaprak Bayrak, Mustafa Yuksekkaya, Ali Kemal Uslubas, Mehmet Esat Kosem, Hasan Yilmaz, Onder Kara, Ozdal Dillioglugil

Erschienen in: International Urology and Nephrology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to assess an “Immunological Profile (IP)” including CD8+ and FoxP3+ T lymphocytes for renal cell carcinoma (RCC) to evaluate its effects on tumor pathological characteristics, disease progression, and survival.

Methods

Adjacent normal and intratumoral specimens from 42 patients who had undergone radical nephrectomy for RCC were analyzed for counts of CD8+ and FoxP3+ T lymphocytes by immunohistochemistry. Tissue from both sites were evaluated and scored separately according to low (0) or high (1) expression of CD8 and FoxP3. A total score (min: 0, max: 4) was assigned to each patient. Thereafter, patients were divided into two groups for clinicopathologic and survival stratification based on score (IP_Weak 0–2; and IP_Strong 3–4). Survival curves were constructed using the Kaplan–Meier method, and a multivariable Cox regression model was used for overall survival (OS) and progression-free survival (PFS).

Results

The mean follow-up was 54.73 ± 21.34 months. Poor RCC characteristics including pT3–T4, tumor necrosis, lymphovascular invasion, lymph node involvement, and larger tumor size were significantly more common in the IP_Weak patients compared to IP_Strong (p < 0.05). Kaplan–Meier analysis showed that IP_Weak patients had worse OS (62.5 vs. 100%; p = 0.006) and PFS (50 vs. 94.4%; p = 0.002) compared to IP_Strong patients. In multivariable analysis, IP_Weak (HR 8.64; 95% CI 1.09–68.05, p = 0.042) and high tumor node metastasis stage (HR 45.33; 95% CI 4.69–437.68, p < 0.001) were significant independent predictors of poor PFS.

Conclusion

Assessment of IP including CD8+ and FoxP3+ T lymphocytes in adjacent normal and intratumoral sites in RCC may serve as a good predictive marker for PFS.

Capitanio U, Bensalah K, Bex A et al (2019) Epidemiology of renal cell carcinoma. Eur Urol 75(1):74–84. https://doi.org/10.1016/j.eururo.2018.08.036CrossRef

Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799–810. https://doi.org/10.1016/j.eururo.2019.02.011CrossRef

Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24(19):3101–3106. https://doi.org/10.1200/JCO.2005.04.8280CrossRefPubMed

Harter PN, Bernatz S, Scholz A et al (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6(38):40836–40849. https://doi.org/10.18632/oncotarget.5696CrossRefPubMedPubMedCentral

Nathan PD, Eisen TG (2002) The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 3(2):89–96. https://doi.org/10.1016/s1470-2045(02)00650-2CrossRefPubMed

Kobayashi M, Morita T, Chun NA, Matsui A, Takahashi M, Murakami T (2012) Effect of host immunity on metastatic potential in renal cell carcinoma: the assessment of optimal in vivo models to study metastatic behavior of renal cancer cells. Tumour Biol 33(2):551–559. https://doi.org/10.1007/s13277-011-0300-4CrossRefPubMed

Lalani AA, McGregor BA, Albiges L et al (2019) Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur Urol 75(1):100–110. https://doi.org/10.1016/j.eururo.2018.10.010CrossRefPubMed

Flippot R, Escudier B, Albiges L (2018) Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs 78(14):1443–1457. https://doi.org/10.1007/s40265-018-0970-yCrossRefPubMed

Anitei MG, Zeitoun G, Mlecnik B et al (2014) Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 20(7):1891–1899. https://doi.org/10.1158/1078-0432.CCR-13-2830CrossRefPubMed

10.

Wang Y, Lin HC, Huang MY et al (2018) The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother 67(3):435–444. https://doi.org/10.1007/s00262-017-2094-8CrossRefPubMed

11.

Li XD, Huang CW, Liu ZF et al (2019) Prognostic role of the immunoscore for patients with urothelial carcinoma of the bladder who underwent radical cystectomy. Ann Surg Oncol 26(12):4148–4156. https://doi.org/10.1245/s10434-019-07529-yCrossRefPubMed

12.

Selvi I, Demirci U, Bozdogan N, Basar H (2020) The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results. Int Urol Nephrol 52:21–34. https://doi.org/10.1007/s11255-019-02285-0CrossRefPubMed

13.

Ling A, Edin S, Wikberg ML, Oberg A, Palmqvist R (2014) The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 110(10):2551–2559. https://doi.org/10.1038/bjc.2014.161CrossRefPubMedPubMedCentral

14.

Yao JX, Chen X, Xi W et al (2018) Immunoscore system for predicting clinical outcome of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. J Cancer 9(22):4099–4107. https://doi.org/10.7150/jca.27408CrossRefPubMedPubMedCentral

15.

Fritzsching B, Fellenberg J, Moskovszky L et al (2015) CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 4(3):e990800. https://doi.org/10.4161/2162402X.2014.990800CrossRefPubMedPubMedCentral

16.

Sideras K, Galjart B, Vasaturo A et al (2018) Prognostic value of intra-tumoral CD8(+) /FoxP3(+) lymphocyte ratio in patients with resected colorectal cancer liver metastasis. J Surg Oncol 118(1):68–76. https://doi.org/10.1002/jso.25091CrossRefPubMedPubMedCentral

17.

Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148. https://doi.org/10.1016/S1470-2045(12)70559-4CrossRefPubMedPubMedCentral

18.

Pages F, Mlecnik B, Marliot F et al (2018) International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128–2139. https://doi.org/10.1016/S0140-6736(18)30789-XCrossRefPubMed

19.

Galon J, Lugli A, Bifulco C et al (2017) World-wide immunoscore task force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016. J Transl Med 15(1):212. https://doi.org/10.1186/s12967-017-1310-9CrossRefPubMedPubMedCentral

20.

Guo C, Zhao H, Wang Y et al (2019) Prognostic value of the neo-immunoscore in renal cell carcinoma. Front Oncol 9:439. https://doi.org/10.3389/fonc.2019.00439CrossRefPubMedPubMedCentral

21.

Zhou C, Diao P, Wu Y et al (2020) Development and validation of a seven-immune-feature-based prognostic score for oral squamous cell carcinoma after curative resection. Int J Cancer 146(4):1152–1163. https://doi.org/10.1002/ijc.32571CrossRefPubMed

22.

Nakano O, Sato M, Naito Y et al (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61(13):5132–5136PubMed

23.

George DJ, Martini JF, Staehler M et al (2018) Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC study. Clin Cancer Res 24(7):1554–1561. https://doi.org/10.1158/1078-0432.CCR-17-2822CrossRefPubMed

24.

Huang Y, Liao H, Zhang Y et al (2014) Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS ONE 9(5):e94376. https://doi.org/10.1371/journal.pone.0094376CrossRefPubMedPubMedCentral

25.

Shaban E, Bayliss G, Malhotra DK et al (2018) Targeting regulatory T cells for transplant tolerance: new insights and future perspectives. Kidney Dis (Basel) 4(4):205–213. https://doi.org/10.1159/000490703CrossRef

26.

Shi JY, Ma LJ, Zhang JW et al (2017) FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-beta/Smad2/3 signaling pathway. BMC Cancer 17(1):648. https://doi.org/10.1186/s12885-017-3633-6CrossRefPubMedPubMedCentral

27.

Zhou Y, Shao N, Aierken N et al (2017) Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis. J Cancer 8(19):4098–4105. https://doi.org/10.7150/jca.21030CrossRefPubMedPubMedCentral

28.

Cavalleri T, Bianchi P, Basso G et al (2019) Combined low densities of FoxP3(+) and CD3(+) tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression. Cancer Immunol Res 7(5):751–758. https://doi.org/10.1158/2326-6066.CIR-18-0661CrossRefPubMed

29.

Hu G, Li Z, Wang S (2017) Tumor-infiltrating FoxP3(+) Tregs predict favorable outcome in colorectal cancer patients: a meta-analysis. Oncotarget 8(43):75361–75371. https://doi.org/10.18632/oncotarget.17722CrossRefPubMedPubMedCentral

30.

Bedke J, Heide J, Ribback S et al (2018) Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int 121(1):84–92. https://doi.org/10.1111/bju.13984CrossRefPubMed

31.

Zigeuner R, Hutterer G, Chromecki T et al (2010) External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 57(1):102–109. https://doi.org/10.1016/j.eururo.2008.11.033CrossRefPubMed

32.

Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179. https://doi.org/10.1038/srep15179CrossRefPubMedPubMedCentral

33.

Galon J, Fox BA, Bifulco CB et al (2016) Immunoscore and immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med 14:273. https://doi.org/10.1186/s12967-016-1029-zCrossRefPubMedPubMedCentral

Titel: Prognostic value of immunological profile based on CD8+ and FoxP3+ T lymphocytes in the peritumoral and intratumoral subsites for renal cell carcinoma
verfasst von: Kerem Teke
Busra Yaprak Bayrak
Mustafa Yuksekkaya
Ali Kemal Uslubas
Mehmet Esat Kosem
Hasan Yilmaz
Onder Kara
Ozdal Dillioglugil
Publikationsdatum: 05.08.2020
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 12/2020
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-020-02592-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Chronic kidney disease and concomitant sleep apnea are associated with increased overall mortality: a meta-analysis

Survival and renal recovery after acute kidney injury requiring dialysis outside of intensive care units

Extracorporeal shock wave lithotripsy for distal ureteric stones: which is the ideal approach?

Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer

Coercion, dissatisfaction, and social stigma: an ethnographic study of compensated living kidney donation in Iran